LOS ANGELES, Oct. 12 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Oculus Innovative Sciences, Inc., (Nasdaq: OCLS) with a twelve month target price of $3.81. Ross Silver, Principal Analyst at Vista Partners stated, "We believe Oculus provides investors with an opportunity to invest in a fast growing medical technology company. Oculus develops, manufactures and markets a family of products, with its partners, intended to help prevent and treat infections in chronic and acute wounds, antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores as well as increase blood flow to the wound site and reduce both inflammation and pain while assisting in faster wound closure." Silver goes on to state, "Oculus is growing significantly as evidenced by their revenue growth of approximately 40% in each of the past two years. In addition, management has provided revenue guidance of $45-$60M in fiscal year 2013, a six fold increase from revenues reported in fiscal year 2010." To download a FREE copy of the Oculus Innovative Sciences, Inc. research report, please visit www.vistap.com/research and complete the research form to gain access to the report.
About Vista Partners:
Vista Partners LLC is an independently owned research and advisory firm with offices in California and Oregon. Vista Partners' professional staff has backgrounds in finance, corporate communications and investment banking.
For a full list of disclosures, please visit our website www.vistap.com/research.
SOURCE Vista Partners